Evidence map›Paper›PMID 37332787›Full record

ArticleACS omega2023

Core-Shell Nanostructured Drug Delivery Platform Based on Biocompatible Metal-Organic Framework-Ligated Polyethyleneimine for Targeted Hepatocellular Carcinoma Therapy.

Mostafa Fytory, Amira Mansour, Waleed M A El Rouby, Ahmed A Farghali, Xiaorong Zhang, Frank Bier, Mahmoud Abdel-Hafiez, Ibrahim M El-Sherbiny

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Nanoscale advances · 2025
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Mostafa FytoryNanomedicine Labs, Center for Materials Science (CMS), Zewail City of Science and Technology, 6 October City, 12578 Giza, Egypt.ORCID https://orcid.org/0000-0001-8783-4515
Amira MansourNanomedicine Labs, Center for Materials Science (CMS), Zewail City of Science and Technology, 6 October City, 12578 Giza, Egypt.
Waleed M A El RoubyMaterial Science and Nanotechnology Department, Faculty of Postgraduate Studies for Advanced Sciences (PSAS), Beni-Suef University, 62511 Beni-Suef, Egypt.ORCID https://orcid.org/0000-0003-0754-7562
Ahmed A FarghaliMaterial Science and Nanotechnology Department, Faculty of Postgraduate Studies for Advanced Sciences (PSAS), Beni-Suef University, 62511 Beni-Suef, Egypt.
Xiaorong ZhangMolecular Bioanalytics and Bioelectronics Group, Institute of Biochemistry and Biology, University of Potsdam, 14476 Potsdam-Golm, Germany.
Frank BierMolecular Bioanalytics and Bioelectronics Group, Institute of Biochemistry and Biology, University of Potsdam, 14476 Potsdam-Golm, Germany.
Mahmoud Abdel-HafiezDepartment of Physics and Astronomy, Uppsala University, Box 516, SE-75120 Uppsala, Sweden.ORCID https://orcid.org/0000-0002-1802-5279
Ibrahim M El-SherbinyNanomedicine Labs, Center for Materials Science (CMS), Zewail City of Science and Technology, 6 October City, 12578 Giza, Egypt.ORCID https://orcid.org/0000-0002-8179-437X
Beni-Suef University · EGUniversity of Potsdam · DEZewail City of Science and Technology · EGUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multifunctional nanosized metal-organic frameworks (NMOFs) have advanced rapidly over the past decade to develop drug delivery systems (DDSs). These material systems still lack precise and selective cellular targeting, as well as the fast release of the quantity of drugs that are simply adsorbed within and on the external surface of nanocarriers, which hinders their application in the drug delivery. Herein, we designed a biocompatible Zr-based NMOF with an engineered core and the hepatic tumor-targeting ligand, glycyrrhetinic acid grafted to polyethyleneimine (PEI) as the shell. The improved core-shell serves as a superior nanoplatform for efficient controlled and active delivery of the anticancer drug doxorubicin (DOX) against hepatic cancer cells (HepG2 cells). In addition to their high loading capacity of 23%, the developed nanostructure DOX@NMOF-PEI-GA showed an acidic pH-stimulated response and extended the drug release time to 9 days as well as enhanced the selectivity toward the tumor cells. Interestingly, the DOX-free nanostructures showed a minimal toxic effect on both normal human skin fibroblast (HSF) and hepatic cancer cell line (HepG2), but the DOX-loaded nanostructures exhibited a superior killing effect toward the hepatic tumor, thus opening the way for the active drug delivery and achieving efficient cancer therapy applications.

Identifiers

PMID37332787
PMCPMC10269253
OpenAlexW4378901630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.